Results 161 to 170 of about 24,692 (192)

Formulation and Evaluation of Ion Activated In-Situ Gelling Ophthalmic Solution containing Brimonidine Tartrate using 32 Factorial Design

Research Journal of Pharmacy and Technology
The objective of the current work is to develop an ion activated in situ gel for treatment of Glaucoma with Brimonidine Tartrate. As conventional eye drops exhibit the demerits of poor bioavailability, naso-lachrymal drainage and rapid pre-corneal ...
Trupti M. Rajamanya, Yogesh S. Thorat, Avinash H. Hosmani, Vaijinath G. Digge   +3 more
semanticscholar   +1 more source

Effect of brimonidine tartrate 0.10% ophthalmic solution on pupil diameter

Journal of Cataract and Refractive Surgery, 2011
To evaluate the effect of brimonidine tartrate 0.10% ophthalmic solution on pupil diameter under light and dark luminance conditions.Ophthalmology Department, Tel Aviv Medical Center, Tel Aviv, Israel.Case series.The pupil diameter was measured with a Colvard pupillometer in eyes of healthy volunteers under light (5.0 candelas [cd]/m(2)) and dark (0.0 ...
Moshe Lazar, Elad Moisseiev, Anat Kesler, Gabi Shemesh   +3 more
openaire   +3 more sources

Effect of brimonidine tartrate 0.2% ophthalmic solution on pupil size

Journal of Cataract and Refractive Surgery, 2004
To evaluate the effect of brimonidine tartrate 0.2% ophthalmic solution on pupil size under scotopic and photopic luminance conditions in persons considering laser refractive surgery.Ophthalmic Health Center, Tel Aviv, Israel.The pupil size was measured in 36 eyes of 36 participants under scotopic and photopic conditions using the Colvard pupillometer (
Levi Rothkoff, Moshe Lazar, Anat Kesler, Gabi Shemesh   +3 more
openaire   +3 more sources

Vitreous and Aqueous Concentrations of Brimonidine Following Topical Application of Brimonidine Tartrate 0.1% Ophthalmic Solution in Humans

Journal of Ocular Pharmacology and Therapeutics, 2015
To determine the vitreous and aqueous concentrations of brimonidine after topical application of the ophthalmic solution 0.1%.The prospective observational case series included patients with an idiopathic epiretinal membrane or macular hole who were scheduled for a pars plana vitrectomy.
Seiko Kozai, Masaru Inatani, Shogo Arimura, Yoshihiro Takamura, Yuji Takihara, Takehiro Matsumura, Satoshi Yokota, Satoshi Yokota, Takeshi Tomomatsu   +8 more
openaire   +2 more sources

Design of ocular inserts of brimonidine tartrate by response surface methodology

Journal of Drug Delivery Science and Technology, 2007
Reservoir-type ocular inserts of brimonidine tartrate have been formulated by solvent casting technique for once a day administration. The drug-loaded core film was produced by casting a hydroalcoholic solution of hydroxyl propyl methyl cellulose (HPMC) (5% w/v) and glycerin (40% w/w).
B. Hulakoti, B.G. Desai, H.N. Shivakumar, Purnima Ashok, P.G. Subhash   +4 more
openaire   +2 more sources

Effect of single and multiple doses of 0.2% brimonidine tartrate in the glaucomatous Beagle

Veterinary Ophthalmology, 2002
AbstractThe objective of this study was to evaluate the changes in intraocular pressure (IOP) in glaucomatous dogs after instillations of 0.2% brimonidine once, twice and three times daily in single day studies, and after twice and three times daily for 4 days in multiple dose studies. We studied eight Beagles with inherited primary open angle glaucoma.
Edward O. MacKay, Kirk N. Gelatt
openaire   +3 more sources

In vitro characterization of a controlled-release ocular insert for delivery of brimonidine tartrate

Acta Biomaterialia, 2014
Glaucoma is the second leading cause of blindness in the US. Brimonidine tartrate (BT) is a modern anti-glaucoma agent that is currently administered as frequently as a thrice-daily topical eye drop medication. Accordingly, compliance with BT regimens is low, limiting overall effectiveness. One attempt that has previously proved effective in addressing
Steven R. Little, Joshua E. Mealy, Morgan V. Fedorchak   +2 more
openaire   +2 more sources

Comparison of the neuroprotective effects of brimonidine tartrate and melatonin on retinal ganglion cells

International Ophthalmology, 2017
We aimed to compare the neuroprotective effects of brimonidine tartrate (BRT) and melatonin (MEL) on retinal ganglion cells (RGCs) in a rat glaucoma model.Thirty-six adult Wistar albino rats were allocated into six groups: control (C), glaucoma (G), BRT, MEL, G + BRT and G + MEL.
Deniz Marangoz, Elif Guzel, Signem Eyuboglu, Asli Gumusel, Ismail Seckin, Ferda Ciftci, Bayram Yilmaz, Ilgaz Yalvac   +7 more
openaire   +5 more sources

The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension

American Journal of Ophthalmology, 2000
To study the effects of topical brimonidine tartrate 0.2%, an alpha(2)-agonist ocular hypotensive drug, on retinal capillary blood flow in patients with ocular hypertension.The study was a double-masked, randomized, placebo-controlled trial set in a tertiary eye center.
Anthony M Carlsson, Balwantray C. Chauhan, A.Arlene Lee, Raymond P. LeBlanc   +3 more
openaire   +3 more sources

Brimonidine Tartrate Poisoning in Children: Frequency, Trends, and Use of Naloxone as an Antidote

Pediatrics, 2009
BACKGROUND. Brimonidine tartrate, a centrally acting selective α-2 adrenergic agonist with a toxicity that is often compared with that of clonidine, is used as eye drops to lower intraocular pressure in glaucoma. We investigated characteristics of childhood exposures to brimonidine-containing products. METHODS.
Noelle Huntington, Melisa Lai Becker, Alan D. Woolf, Alan D. Woolf   +3 more
openaire   +3 more sources